News Related to Grade 3 or Higher Adverse Events

Related coverage linked through entity extraction aliases.

Oral Drug Combo Shows Efficacy for Older AML Patients; Delayed Pegfilgrastim Reduces Breast Cancer Bone Pain

Jun 10, 2026

Two separate clinical trials have reported advances in cancer care. An oral drug combination of decitabine-cedazuridine and venetoclax showed efficacy in older patients with acute myeloid leukemia, with a 47% complete response rate in a phase 2b trial. A separate randomized controlled trial found that delaying pegfilgrastim administration to 72 hours post-chemotherapy significantly reduced bone pain in women with stage I–III breast cancer.

SONIA Trial Finds No Overall Survival Benefit for First-Line CDK4/6 Inhibitors in Advanced Breast Cancer

Apr 02, 2026

The SONIA trial found no overall survival benefit for first-line CDK4/6 inhibitors versus second-line use in advanced HR+/HER2- breast cancer. Median survival was 47.9 vs 48.1 months, though post hoc analysis suggested benefit in premenopausal patients. First-line treatment was associated with more severe adverse events.